Fairness opinions › Acquirers
Danaher: healthcare acquisitions with fairness opinions
4 public-company targets, 2011-2026, $36B combined enterprise value. The multiples Danaher paid and the banker analyses behind each target board's recommendation.
Deals
4
Median EV / EBITDA paid
20.9x
Median EV / revenue paid
5.69x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2026-02-17 | Masimo | Danaher | Diagnostics / Life Sciences | $9.9B | 21.2x | 6.50x | 10.8%–11.8% | Centerview Partners |
| 2023-08-28 | Abcam | Danaher | Diagnostics / Life Sciences | $5.7B | 29.1x | 11.05x | 8.9%–10.8% | Morgan Stanley, Lazard |
| 2015-05-13 | Pall | Danaher | Diagnostics / Life Sciences | $14B | 20.5x | 4.88x | 9.0%–11.0% | Goldman Sachs |
| 2011-02-07 | Beckman Coulter | Danaher | Diagnostics / Life Sciences | $6.8B | 8.4x | 1.86x | 7.0%–9.0% | Goldman Sachs |